DOP2009000201A - Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc - Google Patents

Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc

Info

Publication number
DOP2009000201A
DOP2009000201A DO2009000201A DO2009000201A DOP2009000201A DO P2009000201 A DOP2009000201 A DO P2009000201A DO 2009000201 A DO2009000201 A DO 2009000201A DO 2009000201 A DO2009000201 A DO 2009000201A DO P2009000201 A DOP2009000201 A DO P2009000201A
Authority
DO
Dominican Republic
Prior art keywords
disease
carbaldehido
pirrolo
pirazol
derivatives
Prior art date
Application number
DO2009000201A
Other languages
English (en)
Inventor
Seiji Nukui
Hui Li
Stephanie Anne Scales
Min Teng
Chunfeng Yin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2009000201A publication Critical patent/DOP2009000201A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos y sales farmaceuticamente aceptables de formula A y B: En las que A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 y R10 son como se han definido anteriormente. La invención también se refiere a composiciones farmacéuticas que comprenden los compuestos y sales farmaceuticamente aceptables y a procedimientos de tratamiento de la diabetes mellitus y sus complicaciones, cáncer, isquemia, inflamación, trastornos del sistema nervioso central, enfermedad cardiovascular, enfermedad de Alzheimer y presión de enfermedad dermatológica, enfermedad virales, trastornos inflamatorios o enfermedades en las que el hígado es un órgano diana.
DO2009000201A 2007-02-07 2009-08-07 Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc DOP2009000201A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88874907P 2007-02-07 2007-02-07
US98908607P 2007-11-19 2007-11-19
US2096508P 2008-01-14 2008-01-14

Publications (1)

Publication Number Publication Date
DOP2009000201A true DOP2009000201A (es) 2009-08-31

Family

ID=39493354

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000201A DOP2009000201A (es) 2007-02-07 2009-08-07 Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc

Country Status (19)

Country Link
US (6) US8183255B2 (es)
EP (1) EP2118112B1 (es)
JP (1) JP5161245B2 (es)
KR (1) KR101060892B1 (es)
AP (1) AP2009004958A0 (es)
AU (1) AU2008212625B2 (es)
BR (1) BRPI0807346B8 (es)
CA (1) CA2677572C (es)
CR (1) CR10968A (es)
DO (1) DOP2009000201A (es)
EA (1) EA017937B1 (es)
EC (1) ECSP099569A (es)
IL (1) IL200270A (es)
MA (1) MA31178B1 (es)
MX (1) MX2009008546A (es)
NZ (1) NZ578876A (es)
TN (1) TN2009000331A1 (es)
WO (1) WO2008096260A1 (es)
ZA (1) ZA200906032B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2118112B1 (en) 2007-02-07 2015-07-08 Pfizer Inc. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US9382229B2 (en) 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN102093366B (zh) * 2011-03-04 2012-11-28 中国医学科学院医药生物技术研究所 双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013152198A1 (en) * 2012-04-04 2013-10-10 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904610A1 (en) 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015179847A1 (en) * 2014-05-23 2015-11-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
SG11201804210XA (en) * 2015-11-20 2018-06-28 Mingsight Pharmaceuticals Inc Treatment of autoimmune disease
CN106727582B (zh) * 2015-11-20 2020-06-12 深圳明赛瑞霖药业有限公司 自身免疫疾病的治疗
CA3030429A1 (en) 2016-07-14 2018-01-18 Mingsight Pharmaceuticals, Inc. Treatment of cancer
JP2020522472A (ja) * 2017-05-25 2020-07-30 ミングサイト ファーマシューティカルズ,インク. Pkc阻害剤の固体状態形態
CR20200151A (es) 2017-10-11 2020-05-23 Hoffmann La Roche Compuestos bicíclicos y métodos de utilización de los mismos
US20210069194A1 (en) * 2018-01-17 2021-03-11 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド Taireファミリーキナーゼインヒビターおよびそれらの使用
WO2020140098A1 (en) * 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2022261214A1 (en) * 2021-06-09 2022-12-15 Mingsight Pharmaceuticals, Inc. Compositions comprising pkc-beta inhibitors and processes for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4555547B2 (ja) * 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
KR100919343B1 (ko) * 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
EP2118112B1 (en) 2007-02-07 2015-07-08 Pfizer Inc. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors

Also Published As

Publication number Publication date
JP2010518069A (ja) 2010-05-27
US20100130501A1 (en) 2010-05-27
US9518060B2 (en) 2016-12-13
EP2118112B1 (en) 2015-07-08
KR101060892B1 (ko) 2011-08-31
AU2008212625B2 (en) 2012-07-19
US20170217991A1 (en) 2017-08-03
US20150099743A1 (en) 2015-04-09
US11780853B2 (en) 2023-10-10
AP2009004958A0 (en) 2009-08-31
IL200270A (en) 2014-07-31
US8877761B2 (en) 2014-11-04
TN2009000331A1 (fr) 2010-12-31
EA017937B1 (ru) 2013-04-30
MX2009008546A (es) 2009-10-08
US8183255B2 (en) 2012-05-22
US20220089613A1 (en) 2022-03-24
EP2118112A1 (en) 2009-11-18
US20200002359A1 (en) 2020-01-02
CR10968A (es) 2009-08-27
CA2677572C (en) 2012-12-18
IL200270A0 (en) 2010-04-29
BRPI0807346B8 (pt) 2021-05-25
US11220518B2 (en) 2022-01-11
ZA200906032B (en) 2013-03-27
MA31178B1 (fr) 2010-02-01
AU2008212625A1 (en) 2008-08-14
HK1139130A1 (en) 2010-09-10
BRPI0807346A2 (pt) 2016-07-26
ECSP099569A (es) 2009-09-29
WO2008096260A1 (en) 2008-08-14
KR20090119883A (ko) 2009-11-20
BRPI0807346B1 (pt) 2020-01-07
EA200970670A1 (ru) 2010-02-26
CA2677572A1 (en) 2008-08-14
US10316045B2 (en) 2019-06-11
NZ578876A (en) 2012-12-21
JP5161245B2 (ja) 2013-03-13
US20120202809A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
ECSP099569A (es) Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehído
UY31545A1 (es) Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
WO2008125945A3 (en) 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
CR9954A (es) Derivados de pirazina
ECSP066730A (es) Compuestos y procedimientos para uso
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
UY29503A1 (es) Derivados de amida sustituida y metodos de uso
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
CR11627A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
AR047529A1 (es) Compuestos de quinolina sustituidos
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UA96618C2 (en) 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
DOP2024000239A (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
UY32748A (es) 2-carboxamida-cicloamino-ureas
GT200700097A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6280529A2 (es) DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA